Business Description
Passage Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US7027121000
Share Class Description:
PASG: Ordinary SharesDescription
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.52 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.54 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 32.2 | |||||
| 3-Year EPS without NRI Growth Rate | 33.4 | |||||
| 3-Year FCF Growth Rate | 34.8 | |||||
| 3-Year Book Growth Rate | -44.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 50.44 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.49 | |||||
| 9-Day RSI | 50.73 | |||||
| 14-Day RSI | 49.94 | |||||
| 3-1 Month Momentum % | 13.03 | |||||
| 6-1 Month Momentum % | -23.06 | |||||
| 12-1 Month Momentum % | -50.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.74 | |||||
| Quick Ratio | 3.74 | |||||
| Cash Ratio | 3.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.6 | |||||
| Shareholder Yield % | 3.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -84.36 | |||||
| ROA % | -56.05 | |||||
| ROIC % | -163.66 | |||||
| 3-Year ROIIC % | -104224.07 | |||||
| ROC (Joel Greenblatt) % | -238.56 | |||||
| ROCE % | -62.6 | |||||
| Moat score | 2 | |||||
| Tariff score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.54 | |||||
| Price-to-Tangible-Book | 0.54 | |||||
| EV-to-EBIT | 0.24 | |||||
| EV-to-EBITDA | 0.25 | |||||
| EV-to-FCF | 0.34 | |||||
| Price-to-Net-Current-Asset-Value | 0.92 | |||||
| Price-to-Net-Cash | 1.04 | |||||
| Earnings Yield (Greenblatt) % | 416.67 | |||||
| FCF Yield % | -169.79 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers